# Independent reviewer report

## Review receipt

- Canonical task identity: `/root/mrr_nature_forward_run_1/reviewer_07_adversarial_causal/run2_figure_reporting_fresh`
- Role ID: `figure-narrative-reporting`
- UTC start timestamp: `2026-07-20T15:56:39Z`
- UTC completion timestamp: `2026-07-20T15:59:32Z`
- Review mode: fresh independent review; no other reviewer reports or benchmark answer materials inspected

## Reviewer role

Figure, narrative, and reporting-integrity reviewer. This review is restricted to internal numerical consistency, supplied figure legends, figure-to-text and narrative-to-evidence alignment, units, denominators, uncertainty, and reporting completeness.

## Material inspected and assessment boundary

- `shared/manuscript.md`, SHA-256 `d51224a5ec717a268dadeee2fe9461a7b9d8c833f5b459be2d522a88d5c0006f`
- `shared/nature-journal-profile.json`, SHA-256 `6f6386d213e195d6ec26d0c177568f27753208425a6a15ce139b1ac2235fd6eb`
- `mrr_nature_run_2/00_input_inventory.json`
- `mrr_nature_run_2/02_shared_fact_base.md`, SHA-256 `947b2ed3c744626d5eadc56845b65f223c6b0d4336bd765e3c714acf4ff4a976`
- Contract references: `multi-agent-review.md`, `concern-ledger-and-adjudication.md`, and `biomedical-review-gates.md`

Article type and stage: Nature Article, initial submission.

The packet contains main text and four short figure legends, but no figure images, tables, supplementary information, raw data, model outputs, or code. Consequently, visual-panel integrity, plotted values, axes, image quality/manipulation, and source-data reconciliation are NOT ASSESSABLE. Explicit contradictions and reporting omissions in the supplied text and legends are assessable.

## Journal standard applied

The assessment applies the supplied Nature profile, especially N002 (technical soundness and strength of evidence), N004 (typical display-item count), N006 (Methods sufficient to interpret and replicate results), and N007–N008 (initial-submission organization and combined presentation of text and figures). The four nominal display items are consistent with the profile's typical display-item count, but item count does not establish reporting adequacy. I do not infer a final editorial decision.

## Overall assessment

The manuscript is not reporting-ready for defensible review as a Nature Article. Its central prediction result is represented by three mutually inconsistent AUC values, the reported correlation coefficient and P value are incompatible with the stated eight-tumour denominator under standard Spearman inference, and the text labels a post-selection random subset as independent validation. The therapeutic narrative additionally claims anti-PD-1 sensitization even though every mouse received anti-PD-1 and no untreated comparator is reported. These are not cosmetic defects: they prevent a reader from determining what the figures show and whether the headline claims follow from the displayed study contrasts. Because figure images and source data were not supplied, I cannot determine which reported number, if any, is correct.

## Major strengths

- Results, Methods, and legends use recognizable Figure 1–4 anchors, making several cross-section checks possible.
- The manuscript reports some key denominators in prose: eight tumours, 72 clinical patients, 31 deaths, 46,218 cells, two cell lines, and five mice per xenograft group.
- The text candidly states several limitations relevant to interpretation, including full-cohort model selection, lack of an external cohort, median follow-up of 18 months, and absence of several mouse outcomes.
- The four-display-item architecture is within the typical range stated in Nature profile N004.

## BLOCKING issues

### FRR-01 — `auc_value_conflict`

- Axis: `figures-and-tables`
- Severity: `BLOCKING`
- Claim pointer: Abstract, “AUC of 0.91 for 3-year mortality”; Results subsection “The five-gene score predicts survival,” “validation-set 3-year mortality AUC of 0.84”; Figure 3 legend, “Panel C labels the validation AUC as 0.86.”
- Evidence pointer: the three supplied manuscript locations above; figure image and model output are unavailable.
- Concern: One central performance estimate is assigned three different values (0.91, 0.84, and 0.86). The discrepancy is large enough to change the apparent performance and leaves no authoritative value for the headline claim.
- Resolution test: Recompute or retrieve the locked analysis from traceable patient-level/model output; make the endpoint, analysis set, estimator, and single authoritative AUC identical in Abstract, Results, and Figure 3; provide the corresponding uncertainty interval and auditable source output.
- Journal gate: Nature profile N002 and N006; universal claim gate.
- Confidence: `1.00`.

### FRR-02 — `anti_pd1_sensitization_contrast_absent`

- Axis: `claim-moderation`
- Severity: `BLOCKING`
- Claim pointer: Abstract, “sensitized xenografts to anti-PD-1 treatment”; Results subsection “EVA1 perturbation supports a therapeutic mechanism,” “EVA1 inhibition sensitizes HCC to anti-PD-1”; Figure 4 legend, “Cell growth and xenograft volume following EVA1 depletion.”
- Evidence pointer: Mouse experiment Methods, “All mice received anti-PD-1,” with only control versus EVA1-depleted cells.
- Concern: The displayed experiment can compare EVA1 status under anti-PD-1 exposure, but it cannot estimate sensitization to anti-PD-1 because there is no untreated anti-PD-1 comparator within each EVA1 condition and therefore no treatment-by-EVA1 interaction. The Figure 4 narrative does not close to the headline therapeutic claim.
- Resolution test: Either narrow all text and legend claims to the observed contrast (smaller day-21 xenografts after EVA1 depletion among mice receiving anti-PD-1) or provide a prespecified factorial comparison with anti-PD-1-treated and untreated arms for both EVA1 conditions, report the interaction estimate with uncertainty, and make Figure 4 display that contrast.
- Journal gate: Nature profile N002 and universal claim gate.
- Confidence: `1.00`.

## MAJOR issues

### FRR-03 — `spearman_n_p_incompatibility`

- Axis: `figures-and-tables`
- Severity: `MAJOR`
- Claim pointer: Results subsection “Single-cell discovery identifies an immune-evasion programme,” “Spearman r = −0.41, P = 0.03”; Figure 2 legend, “Association between EVA1 expression and the T-cell score in eight tumours.”
- Evidence pointer: the Results estimate and the Figure 2 denominator.
- Concern: For eight independent tumours, a two-sided Spearman correlation of magnitude 0.41 does not yield P = 0.03 under standard exact or asymptotic inference (the usual large-sample approximation is approximately P = 0.31). If another unit, test, or model generated P = 0.03, it is not reported. Thus the coefficient, P value, denominator, or test specification is wrong or incomplete.
- Resolution test: Recalculate from the eight tumour-level pairs and reconcile Figure 2, Results, and Methods; report the exact independent unit, handling of ties, test implementation, coefficient, P value, and preferably a confidence interval. If a different analysis was used, name it and align the narrative with that analysis.
- Journal gate: Nature profile N002 and N006.
- Confidence: `0.99`.

### FRR-04 — `three_year_auc_censoring_undefined`

- Axis: `statistical-rigor`
- Severity: `MAJOR`
- Claim pointer: Abstract, “AUC ... for 3-year mortality”; Results, “Because median follow-up was 18 months, 3-year outcome status was unavailable for many surviving patients.”
- Evidence pointer: Study population Methods (31 deaths; median follow-up among survivors 18 months), Statistical analysis, Results, and Figure 3 legend.
- Concern: The manuscript does not state whether the 3-year AUC is a time-dependent survival AUC, how censoring before three years was handled, how many patients were observable or at risk at three years, or any confidence interval. A conventional binary AUC would have undefined or selectively missing outcomes for many survivors. The reported performance is therefore not interpretable even after the numerical discrepancy is corrected.
- Resolution test: Define the 3-year estimand and estimator; report censoring handling, the number at risk/with known status and event count at three years in each analysis set, uncertainty intervals, and enough Figure 3 annotation to distinguish a time-dependent survival ROC from an ordinary ROC.
- Journal gate: Nature profile N002 and N006; clinical cohort and biomarker reporting gates.
- Confidence: `0.98`.

### FRR-05 — `validation_subset_mislabeled_independent`

- Axis: `writing-clarity`
- Severity: `MAJOR`
- Claim pointer: Discussion, “The score was validated in an independent subset”; Figure 3 legend, “Development and validation”; Methods, “stepwise selection using the entire 72-patient dataset” followed by a 70:30 split of “The same 72 patients.”
- Evidence pointer: Score construction and validation Methods and Figure 3 legend.
- Concern: The “validation” subset is not independent of feature selection, coefficient/cutoff selection, or the source cohort. Calling it independent creates a false narrative boundary and overstates what Figure 3 can demonstrate.
- Resolution test: Relabel the subset and Figure 3 as an internal, post-selection split evaluation and remove claims of independence, or rebuild the analysis so all feature, coefficient, cutoff, and missing-data choices are frozen without use of a genuinely held-out cohort and report that cohort's provenance.
- Journal gate: Nature profile N002; biomarker reporting gate.
- Confidence: `1.00`.

### FRR-06 — `score_definition_unreported`

- Axis: `reproducibility`
- Severity: `MAJOR`
- Claim pointer: Impact and implications, “can be measured at diagnosis and used to select anti-PD-1 therapy”; Data and code availability, “model code, coefficient values ... are not deposited”; Methods, “Expression cutoffs, coefficient signs, and missing-value rules were also chosen using the full dataset.”
- Evidence pointer: Score construction Methods, Data and code availability, and absence of a supplied table or supplement containing the formula.
- Concern: The five-gene score is not computable from the report because gene identities, coefficients, signs, cutoffs, assay/normalization requirements, and missing-value rules are not given. Neither Figure 3's legend nor any supplied table closes this gap. An “immediately deployable” or clinically actionable score must at minimum be defined.
- Resolution test: Provide a fixed, complete scoring specification (gene identities, coefficients/direction, intercept or baseline definition if applicable, expression scale and assay, normalization, cutoff, and missing-data rules) in the main text/table or durable supplement, and supply code that reproduces patient-level scores from named inputs.
- Journal gate: Nature profile N006; biomarker and reproducibility gates.
- Confidence: `1.00`.

### FRR-07 — `quantitative_display_reporting_incomplete`

- Axis: `figures-and-tables`
- Severity: `MAJOR`
- Claim pointer: Figure legends 1–4; Results values “24%,” “19%,” “hazard ratio 2.4,” and mouse “P = 0.048.”
- Evidence pointer: all four supplied legends and corresponding Results paragraphs.
- Concern: The legends are not self-contained quantitative reports. They omit panel-by-panel sample sizes and independent biological units, units and scale definitions, summary-statistic and error-bar definitions, exact tests, uncertainty intervals, and replication information. Figure 4 does not state tumour-volume units or show in the legend that n = 5 per group; the cell-growth percentages have no replicate count or uncertainty. The hazard ratio and AUC are also reported without confidence intervals. This prevents readers from judging effect magnitude and precision even if the missing images were otherwise adequate.
- Resolution test: For every panel, state the biological and technical n, what each point represents, units/scales, summary and error-bar definitions, test and sidedness, exact P values where applicable, effect size with confidence interval, exclusions, and replicate structure; align all values with Results and Methods.
- Journal gate: Nature profile N002 and N006.
- Confidence: `0.99`.

### FRR-08 — `cell_points_obscure_patient_unit`

- Axis: `figures-and-tables`
- Severity: `MAJOR`
- Claim pointer: Figure 1 legend, “Each point in the differential-expression panel represents one cell”; Methods, eight patients and “Cells were treated as independent observations.”
- Evidence pointer: Single-cell discovery Methods and Figure 1 legend.
- Concern: Figure 1 foregrounds 46,218 cell-level points while omitting the eight-patient nesting that defines biological replication. The legend does not identify patient contributions, patient-level variability, or whether high/low infiltration is assigned at the tumour level. This visual framing can make the evidence appear to have tens of thousands of independent replicates.
- Resolution test: Display or annotate patient identity and group-level patient denominators, report patient-level effect summaries or a model respecting patient nesting, and ensure the legend explicitly separates cell count from independent tumour count.
- Journal gate: Nature profile N002 and N006; single-cell reporting gate.
- Confidence: `1.00`.

## MINOR issues

### FRR-09 — `terminology_and_endpoint_labels`

- Axis: `writing-clarity`
- Severity: `MINOR`
- Claim pointer: Abstract and Figure 3 use “3-year mortality,” whereas Results and Methods frame the endpoint as overall survival; Results use “Spearman r” rather than explicitly identifying Spearman's rho.
- Evidence pointer: Abstract, Statistical analysis, Results survival subsection, and Figure 3 legend.
- Concern: Endpoint and statistic notation are not fully harmonized. “Three-year mortality” and a survival-model endpoint require a precise relation, especially with censoring; “Spearman r” may be confused with Pearson's r.
- Resolution test: Use one prespecified endpoint label throughout, define its time origin and censoring, and label the rank coefficient as Spearman's rho (or an unambiguous equivalent).
- Journal gate: Nature profile N006.
- Confidence: `0.95`.

## EDITORIAL issues

### FRR-10 — `legends_lack_panel_map`

- Axis: `writing-clarity`
- Severity: `EDITORIAL`
- Claim pointer: Figure legends 1, 2, and 4 have no panel letters or panel-specific descriptions; Figure 3 mentions only Panel C.
- Evidence pointer: supplied Figure legends.
- Concern: The legends do not provide a complete panel map, making text-to-panel navigation impossible to verify and likely difficult for readers.
- Resolution test: Add a concise A–n description for every panel and use matching panel citations in Results.
- Journal gate: Nature profile N007.
- Confidence: `0.98`.

## Claim-ceiling risks

- Figure 2 can support, at most, an exploratory tumour-level association after its coefficient and P value are corrected; it cannot by itself support “EVA1 excludes T cells.”
- Figure 3 can support, at most, an internally evaluated, post-selection prognostic association in this single-centre cohort; the supplied reporting cannot support independent validation, clinical actionability, treatment selection, or universal applicability.
- Figure 4 can support, at most, reduced 72-hour growth in the reported cell-line conditions and a day-21 xenograft-volume difference between EVA1 conditions while all animals received anti-PD-1. It cannot isolate anti-PD-1 sensitization, immune escape, or readiness for therapeutic development.
- Cross-modal concordance does not remove the missing denominators, uncertainty, comparator arms, or external-validation boundary.

## Required versus optional additional work

Required to retain any central performance or therapeutic claim:

1. Reconcile the AUC and correlation results against auditable outputs and harmonize all text/legend values.
2. Define the 3-year survival-performance estimand, censoring method, denominator/event counts, and uncertainty.
3. Correct the “independent validation” label or perform a genuinely untouched validation.
4. Provide the complete locked score definition and reproducible calculation path.
5. Make every legend self-contained with denominators, units, uncertainty, tests, and panel mapping.
6. Narrow the anti-PD-1 sensitization claim to the tested contrast, or supply an experiment capable of estimating sensitization and show that contrast.
7. Separate patient-level from cell-level replication in Figure 1 and its inference.

Optional presentation-strengthening work:

- Add a cohort flow display and a compact table of analysis-set denominators.
- Add a calibration plot and benchmark comparison only if supported by a valid analysis; these cannot repair leakage or replace external validation.
- Add direct-value labels where they improve readability after source reconciliation.

## Journal-fit posture

As reported, the figure and quantitative narrative package does not meet the supplied Nature profile's evidence-strength and interpretability expectations. The broad four-figure architecture is plausible, but central numeric contradictions and unsupported narrative labels preclude a defensible high-confidence assessment of the main claims. This is a reviewer posture, not a prediction of the journal's editorial decision.

## NOT ASSESSABLE items

- Figure images: visual accuracy, axes, scales, colour accessibility, image integrity, panel completeness, and whether plotted values match legends.
- Tables and supplementary information: no assessment of tabular denominators, patient characteristics, model coefficients, full statistical outputs, or supplementary figure closure.
- Source-data reconciliation: no raw data, patient-level outputs, model objects, or code were supplied, so no reported value can be independently reproduced.
- Image-derived claims: tumour measurements, bands, microscopy fields, gating, representative-image selection, and exclusions are not assessable.
- Whether any absent material exists outside this review packet; absence from the supplied packet is not treated as proof that it was never produced.

## Evidence anchors

- Abstract: “AUC of 0.91 for 3-year mortality.”
- Results, “The five-gene score predicts survival”: AUC 0.84 and incomplete three-year status.
- Figure 3 legend: Panel C AUC 0.86.
- Figure 2 legend and corresponding Results: eight tumours; Spearman r = −0.41, P = 0.03.
- Score construction and validation Methods: full-cohort selection before the 70:30 split.
- Mouse experiment Methods: all ten mice received anti-PD-1.
- Figure 4 legend and functional Results: growth reductions and xenograft volume without legend-level units, uncertainty, or replicate definitions.
- Data and code availability: coefficients, model code, and patient-level data not deposited.
- Figure 1 legend and Single-cell discovery Methods: one point per cell and cells treated as independent.

## Confidence and reasons

Overall confidence: `0.99` for the text-level numerical contradictions, denominators, label mismatches, and omissions because they are explicit in the supplied manuscript. Confidence is intentionally not assigned to the unseen figures' visual correctness or to which discrepant numerical value is true; those items remain NOT ASSESSABLE without the figure images and source outputs.
